Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 18/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5459971 | 0.92 | TACR1 (0.65) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL5457103 | 0.90 | TACR1 (0.56) | TACR1SCN5ASCN9A | |
| SCHEMBL5460696 | 0.90 | TACR1 (0.59) | TACR1SCN5ASCN9AOPRK1 | |
| Figopitant SCHEMBL21955647 | 0.88 | TACR1 (0.59) | TACR1SCN5ASCN9ATACR3 | |
| Figopitant SCHEMBL226054 | 0.88 | TACR1 (0.59) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL5460608 | 0.87 | TACR1 (0.56) | TACR1OPRK1 | |
| SCHEMBL3475643 | 0.87 | TACR1 (0.58) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL6836750 | 0.87 | TACR1 (0.58) | TACR1SCN5ASCN9ATACR3 | |
| SCHEMBL5455442 | 0.86 | TACR1 (0.54) | TACR1 | |
| SCHEMBL3475829 | 0.86 | TACR1 (0.57) | TACR1SCN5ASCN9ATACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | ASTRAZENECA AB (SE) | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203139-A1 | Aryl Glycinamide Derivatives And Their Use As Nk1 Antagonists And Serotonin Reuptake Inhibitors | TPH1, NTSR1, HTR1D | TACR1 68/4885SCN5A 1603/4885SCN9A 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.